MX2024002406A - Anticuerpos anti-her2 y metodos para su uso. - Google Patents
Anticuerpos anti-her2 y metodos para su uso.Info
- Publication number
- MX2024002406A MX2024002406A MX2024002406A MX2024002406A MX2024002406A MX 2024002406 A MX2024002406 A MX 2024002406A MX 2024002406 A MX2024002406 A MX 2024002406A MX 2024002406 A MX2024002406 A MX 2024002406A MX 2024002406 A MX2024002406 A MX 2024002406A
- Authority
- MX
- Mexico
- Prior art keywords
- subdomain
- antibodies
- methods
- chain polypeptide
- human her2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163237104P | 2021-08-25 | 2021-08-25 | |
| PCT/US2022/075438 WO2023028543A2 (en) | 2021-08-25 | 2022-08-25 | Anti-her2 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002406A true MX2024002406A (es) | 2024-04-03 |
Family
ID=85322213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002406A MX2024002406A (es) | 2021-08-25 | 2022-08-25 | Anticuerpos anti-her2 y metodos para su uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20250136713A1 (https=) |
| EP (1) | EP4392458A4 (https=) |
| JP (1) | JP2024534118A (https=) |
| KR (1) | KR20240052019A (https=) |
| CN (1) | CN117980342A (https=) |
| AR (1) | AR126873A1 (https=) |
| AU (1) | AU2022333088A1 (https=) |
| CA (1) | CA3229542A1 (https=) |
| IL (1) | IL311003A (https=) |
| MX (1) | MX2024002406A (https=) |
| TW (1) | TW202328186A (https=) |
| WO (1) | WO2023028543A2 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| AU2014357292B2 (en) * | 2013-11-27 | 2020-06-25 | Zymeworks Bc Inc. | Bispecific antigen-binding constructs targeting HER2 |
| SG11201608192SA (en) * | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| EP3609580A4 (en) * | 2017-04-09 | 2021-03-24 | Combio Pharmaceutical, Inc. | COMMON LIGHT CHAIN BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES AND METHOD OF USE |
-
2022
- 2022-08-25 WO PCT/US2022/075438 patent/WO2023028543A2/en not_active Ceased
- 2022-08-25 AU AU2022333088A patent/AU2022333088A1/en active Pending
- 2022-08-25 IL IL311003A patent/IL311003A/en unknown
- 2022-08-25 TW TW111132034A patent/TW202328186A/zh unknown
- 2022-08-25 EP EP22862264.3A patent/EP4392458A4/en active Pending
- 2022-08-25 CN CN202280057349.1A patent/CN117980342A/zh active Pending
- 2022-08-25 MX MX2024002406A patent/MX2024002406A/es unknown
- 2022-08-25 US US18/685,587 patent/US20250136713A1/en active Pending
- 2022-08-25 JP JP2024511975A patent/JP2024534118A/ja active Pending
- 2022-08-25 AR ARP220102290A patent/AR126873A1/es unknown
- 2022-08-25 KR KR1020247009991A patent/KR20240052019A/ko active Pending
- 2022-08-25 CA CA3229542A patent/CA3229542A1/en active Pending
-
2025
- 2025-10-08 US US19/352,786 patent/US20260109781A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4392458A2 (en) | 2024-07-03 |
| AR126873A1 (es) | 2023-11-22 |
| CN117980342A (zh) | 2024-05-03 |
| WO2023028543A3 (en) | 2023-06-08 |
| US20250136713A1 (en) | 2025-05-01 |
| IL311003A (en) | 2024-04-01 |
| CA3229542A1 (en) | 2023-03-02 |
| KR20240052019A (ko) | 2024-04-22 |
| EP4392458A4 (en) | 2025-11-19 |
| WO2023028543A2 (en) | 2023-03-02 |
| AU2022333088A1 (en) | 2024-03-07 |
| US20260109781A1 (en) | 2026-04-23 |
| JP2024534118A (ja) | 2024-09-18 |
| TW202328186A (zh) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552122A1 (en) | Antibodies and fusion proteins that bind to ccr8 and uses thereof | |
| MX2022010161A (es) | Proteínas biespecíficas anti-her2 diseñadas. | |
| ZA202002338B (en) | Novel bispecific polypeptide complexes | |
| ZA202103717B (en) | Bispecific antibody and use thereof | |
| MX2023010499A (es) | Anticuerpos heterodimericos que se unen a cd3 y cldn6. | |
| PH12020552221A1 (en) | Anti-pd-1 antibodies and uses thereof | |
| EA202090718A1 (ru) | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) | |
| EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
| DOP2012000052A (es) | Proteínas terapéuticas de unión a dll4 | |
| MX2023001556A (es) | Anticuerpos que se dirigen a egfr y uso de los mismos. | |
| WO2022082073A3 (en) | Compositions and methods for muc18 targeting | |
| DOP2012000240A (es) | Proteínas terapéuticas de unión a dll4 | |
| MX2024005712A (es) | Moleculas de anticuerpo y conjugados. | |
| MX2021000439A (es) | Anticuerpos de antigeno anti-tf humanizado. | |
| WO2022051591A3 (en) | Nectin-4 antibodies and uses thereof | |
| MX2022013882A (es) | Anticuerpos dirigidos contra el miembro a de la familia de dominios de lectina tipo c 12 (clec12a) y uso de los mismos. | |
| MX2022015475A (es) | Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma. | |
| MX2020002301A (es) | Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico. | |
| MY204733A (en) | Anti-pd-l1 antibodies and use thereof | |
| CO2023009626A2 (es) | Métodos de tratamiento del cáncer usando anticuerpos anti-tigit en combinación con anticuerpos anti-pd1 | |
| MX2025001452A (es) | Anticuerpos anti-ccr8 y metodos de uso | |
| MX2023006777A (es) | Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2). | |
| MX2024002406A (es) | Anticuerpos anti-her2 y metodos para su uso. | |
| MX2025006929A (es) | Anticuerpos contra la proteína 1 que contiene dominio de cub (cdcp1) y usos de estos | |
| MX2025001591A (es) | Proteinas de union a nkg2d, cd16 y ceacam5 |